Clinical Trial Update: A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of GC4419 in combination with chemoradiation for head and neck squamous cell carcinomas, including cancers of the oral cavity an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• GC4419

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx | Phase 1 | Status: COMPLETED